1 paper2 findings
KDMAge acceleration
upin humans1OR 1.025
KDMAge acceleration is associated with cardiovascular-kidney-metabolic syndrome baseline stage burden in humans (ORs 1.025 (95% CI 1.006–1.044), 1.038 (1.019–1.057), and 1.041 (1.011–1.073) for stages 1, 2/3, and 4 versus stage 0).
“KDMAge acceleration ORs were 1.025 (95% CI 1.006-1.044; P = 0.012), 1.038 (95% CI 1.019-1.057; P < 0.001), and 1.041 (95% CI 1.011-1.073; P = 0.010).”
HumansNHANES; stages 1, 2/3, and 4 versus stage 0n = 5,228
Higher biological age linked to worsening disease stages
Renal failure11 Oct 2026
PhenoAge
upin humans1OR 1.154
PhenoAge is associated with cardiovascular-kidney-metabolic syndrome baseline stage burden in humans (ORs 1.154 (95% CI 1.107–1.202), 1.221 (1.176–1.268), and 1.333 (1.249–1.423) for stages 1, 2/3, and 4 versus stage 0).
“In NHANES, PhenoAge acceleration was associated with stages 1, 2/3, and 4 versus stage 0.”
HumansNHANES; stages 1, 2/3, and 4 versus stage 0n = 5,228
Higher biological age linked to worsening disease stages
Renal failure11 Oct 2026
Over a median 13.48 years, 2,567 UK Biobank participants progressed from stage 0 or 1 to stage 2 or 3 of the syndrome.Over a median 13.48 years, 2,567 UK Biobank participants progressed from stage 0 or 1 to stage 2 or 3 of the syndrome.